These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33188747)

  • 21. Epidemiology and control of intestinal parasites with nitazoxanide in children in Mexico.
    Diaz E; Mondragon J; Ramirez E; Bernal R
    Am J Trop Med Hyg; 2003 Apr; 68(4):384-5. PubMed ID: 12875284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study.
    Richter JM; Kushkuley S; Barrett JA; Oster G
    Aliment Pharmacol Ther; 2012 Aug; 36(3):248-56. PubMed ID: 22690748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of intestinal parasites, with emphasis on the molecular epidemiology of Giardia duodenalis and Blastocystis sp., in the Paranaguá Bay, Brazil: a community survey.
    Seguí R; Muñoz-Antoli C; Klisiowicz DR; Oishi CY; Köster PC; de Lucio A; Hernández-de-Mingo M; Puente P; Toledo R; Esteban JG; Carmena D
    Parasit Vectors; 2018 Aug; 11(1):490. PubMed ID: 30165880
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
    D'Haens G; Hommes D; Engels L; Baert F; van der Waaij L; Connor P; Ramage J; Dewit O; Palmen M; Stephenson D; Joseph R
    Aliment Pharmacol Ther; 2006 Oct; 24(7):1087-97. PubMed ID: 16984503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study.
    Meucci G; Fasoli R; Saibeni S; Valpiani D; Gullotta R; Colombo E; D'Incà R; Terpin M; Lombardi G;
    Inflamm Bowel Dis; 2012 Jun; 18(6):1006-10. PubMed ID: 21830282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis.
    D'Haens G; Sandborn WJ; Barrett K; Hodgson I; Streck P
    Am J Gastroenterol; 2012 Jul; 107(7):1064-77. PubMed ID: 22565161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients.
    Solomon D; Yarlas A; Hodgkins P; Karlstadt R; Yen L; Kane S
    Aliment Pharmacol Ther; 2012 Jun; 35(12):1386-96. PubMed ID: 22536781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study.
    Hyams JS; Davis S; Mack DR; Boyle B; Griffiths AM; LeLeiko NS; Sauer CG; Keljo DJ; Markowitz J; Baker SS; Rosh J; Baldassano RN; Patel A; Pfefferkorn M; Otley A; Heyman M; Noe J; Oliva-Hemker M; Rufo P; Strople J; Ziring D; Guthery SL; Sudel B; Benkov K; Wali P; Moulton D; Evans J; Kappelman MD; Marquis A; Sylvester FA; Collins MH; Venkateswaran S; Dubinsky M; Tangpricha V; Spada KL; Britt A; Saul B; Gotman N; Wang J; Serrano J; Kugathasan S; Walters T; Denson LA
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):855-868. PubMed ID: 28939374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
    Clemett D; Markham A
    Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
    Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
    Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adherence, risk factors of non-adherence and patient's preferred treatment strategy of mesalazine in ulcerative colitis: multicentric observational study.
    Keil R; Wasserbauer M; Zádorová Z; Kojecký V; Hlava Š; Št'ovíček J; Chudý J; Roznětinská M; Drábek J; Kubišová N; Lochmannová J
    Scand J Gastroenterol; 2018 Apr; 53(4):459-465. PubMed ID: 29560753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis.
    Pedersen N; Thielsen P; Martinsen L; Bennedsen M; Haaber A; Langholz E; Végh Z; Duricova D; Jess T; Bell S; Burisch J; Munkholm P
    Inflamm Bowel Dis; 2014 Dec; 20(12):2276-85. PubMed ID: 25248002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of mesalazine or beclomethasone dipropionate enema or their combination in patients with distal active ulcerative colitis.
    Crispino P; Pica R; Unim H; Rivera M; Cassieri C; Zippi M; Paoluzi P
    Eur Rev Med Pharmacol Sci; 2015 Aug; 19(15):2830-7. PubMed ID: 26241537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids.
    Bello C; Belaiche J; Louis E; Reenaers C
    J Crohns Colitis; 2011 Jun; 5(3):196-202. PubMed ID: 21575881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis.
    Lichtenstein GR; Ramsey D; Rubin DT
    Aliment Pharmacol Ther; 2011 Mar; 33(6):672-8. PubMed ID: 21255059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial.
    Lang A; Salomon N; Wu JC; Kopylov U; Lahat A; Har-Noy O; Ching JY; Cheong PK; Avidan B; Gamus D; Kaimakliotis I; Eliakim R; Ng SC; Ben-Horin S
    Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1444-9.e1. PubMed ID: 25724700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial.
    Rubin DT; Bradette M; Gabalec L; Dobru D; Márquez J; Inglis S; Magee E; Solomon D; D'Haens G;
    J Crohns Colitis; 2016 Aug; 10(8):925-33. PubMed ID: 26908939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is maintenance therapy always necessary for patients with ulcerative colitis in remission?
    Ardizzone S; Petrillo M; Imbesi V; Cerutti R; Bollani S; Bianchi Porro G
    Aliment Pharmacol Ther; 1999 Mar; 13(3):373-9. PubMed ID: 10102971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mesalazine allergy in a boy with ulcerative colitis: clinical usefulness of mucosal biopsy criteria.
    Wada S; Kumagai H; Yokoyama K; Ito T; Miyauchi A; Sakamoto S; Imagawa T; Tulyeu J; Tanaka M; Yamagata T
    Clin J Gastroenterol; 2016 Oct; 9(5):302-5. PubMed ID: 27503129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial.
    Gionchetti P; Ardizzone S; Benvenuti ME; Bianchi Porro G; Biasco G; Cesari P; D'albasio G; De Franchis R; Monteleone G; Pallone F; Ranzi T; Trallori G; Valpiani D; Vecchi M; Campieri M
    Aliment Pharmacol Ther; 1999 Mar; 13(3):381-8. PubMed ID: 10102972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.